CVRx lowers 2026 outlook, Canaccord keeps Buy for CVRx stock

CVRx (ISIN US1266381052) lowered its fiscal 2026 revenue outlook to USD 58.00 million to USD 60.00 million on October 12, 2026, while Investing.com reported on September 22, 2026 that Canaccord Genuity kept a Buy rating and a USD 5.00 target for CVRx stock. The reset puts sales execution and reimbursement at the center of the investment case.

Guidance falls below earlier view

Benzinga reported that CVRx generated USD 15.70 million of revenue in the second quarter of fiscal 2026, up 16.00 percent from the prior-year quarter. Gross margin reached 87.00 percent, while the company said the second half would be weaker than the first.

ScanX News reported that the revised fiscal 2026 outlook also includes operating expenses of USD 99.00 million to USD 101.00 million. The expected third-quarter revenue range is USD 13.50 million to USD 14.50 million, creating a lower near-term hurdle than the second-quarter result.

What does the reset change?

Management attributed the change to salesforce productivity issues in regions affected by high turnover and new hires. The earnings call said roughly 60.00 percent of quota-carrying territory managers had joined during the previous 18 months, making onboarding and training a key operational variable.

The reimbursement picture is mixed. Benzinga reported that the overall 30-day Medicare Advantage prior-authorization approval rate reached 60.00 percent in the second quarter, compared with 44.00 percent in 2025. Cash and cash equivalents stood at USD 64.60 million on June 30, 2026.

Leadership and next reporting date

MarketScreener reported on September 21, 2026 that John Landry was appointed chief financial officer effective October 12, 2026, bringing more than 20 years of medical-device finance experience. The appointment adds a new finance leader as CVRx works through its sales reset.

MarketBeat lists November 4, 2026 as the estimated date for CVRx's third-quarter results and expects revenue of USD 13.93 million. That estimate sits inside the company's USD 13.50 million to USD 14.50 million range.

Market value after the outlook cut

CVRx had a market capitalization of USD 36.10 million as of October 13, 2026. The company develops and commercializes Barostim, an implantable neuromodulation system for cardiovascular disease, and its Nasdaq listing uses the ticker CVRX.

Chronology: CVRx appointed John Landry chief financial officer on September 21, 2026, with more than 20 years of medical-device finance experience. The company reported USD 15.70 million of second-quarter fiscal 2026 revenue on October 12, 2026, up 16.00 percent year over year. On the same date, it set fiscal 2026 revenue guidance at USD 58.00 million to USD 60.00 million.

Dates: The estimated third-quarter results date is November 4, 2026.

Market context: Market report S&P 500.

More news and analyses on CVRx stock